Doliver Advisors LP Boosts Stock Position in Novo Nordisk A/S (NYSE:NVO)

Doliver Advisors LP raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 54.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,225 shares of the company’s stock after purchasing an additional 5,721 shares during the period. Doliver Advisors LP’s holdings in Novo Nordisk A/S were worth $1,396,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S during the 2nd quarter valued at $25,000. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S in the third quarter valued at about $28,000. Abound Wealth Management raised its stake in Novo Nordisk A/S by 257.4% during the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after buying an additional 157 shares in the last quarter. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $42,000. Finally, Carolina Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $48,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on NVO shares. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average price target of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO traded down $2.67 during midday trading on Monday, hitting $84.98. 7,893,448 shares of the company’s stock were exchanged, compared to its average volume of 5,355,030. Novo Nordisk A/S has a twelve month low of $81.50 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market cap of $381.35 billion, a P/E ratio of 27.50, a PEG ratio of 1.37 and a beta of 0.45. The stock’s 50 day moving average price is $103.06 and its 200-day moving average price is $121.08.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.